Zoetis has announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has approved Apoquel (oclacitinib tablet) in the European Union for the treatment of pruritus associated…

Zoetis has announced the launch of Apoquel (oclacitinib maleate), a new treatment for pruritus associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. 

Uniquely, the new treatment inhibits the JAK enzyme, a protein…

Zoetis has announced that it has upscaled production of Apoquel, the oral therapy for the treatment of canine pruritus, and it is now available to all UK vet practices on unlimited distribution.

The company says that there was unprecedented demand for…

Zoetis has announced a spring offer on Apoquel, its anti-pruritic for dogs.

The offer is timed to coincide with the expected increase in canine pruritis as the warmer weather leads to increased levels of common allergens such as pollen, dust mites…

Zoetis has launched new 'Switch off the itch' waiting room materials to highlight the problem of skin allergies and encourage dog owners to ask their vet for advice.

Drawing attention to the symptoms of allergic skin disease that owners should…

Zoetis has launched Cytopoint (lokivetmab), a novel once-monthly injectable treatment for the clinical signs of atopic dermatitis in dogs and the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use.

Zoetis says that…

Zoetis is inviting vets to come to its Skinsights Learning Academy, taking place in the theatre on the company's stand at the London Vet Show.

The company says its Skinsights Learning Academies help support individuals and practices improve the healthcare…

Zoetis has announced that the licence for Cytopoint (lokivetmab) has been extended to include the treatment of pruritus associated with allergic dermatitis in dogs.

Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises…

Zoetis has published a technical bulletin for veterinary professionals on the responsible use of parasiticides in dermatology.

The guidance was written by Hany Elsheikha, Head of the European Scientific Counsel for Companion Animal Parasites (ESCCAP).

Zoetis has added a dermatology application to its Vetscan Imagyst, which promises to reduce the time it takes GP veterinary surgeons to analyse skin samples by as much as half.
The new Vetscan Imagyst AI dermatology application analyses impression smears…

Zoetis has announced that all UK veterinary wholesalers have been supplied with stocks of the new chewable form of Apoquel (oclacitinib).

Apoquel chewable tablets were approved by the Veterinary Medicines Directorate (VMD) in November 2021.

Apoquel Chewable…

Zoetis has announced that Apoquel (oclacitinib), its treatment for atopic dermatitis and associated pruritis, will be available in palatable chew form in the UK next year, following the grant of a marketing authorisation.

Developed by Zoetis, Apoquel is…